We are live on ! Find out more
NRD

Nebula Research & Development Portfolio holdings

AUM $1.17B
1-Year Est. Return 15.19%
This Fund
S&P 500
This Quarter Est. Return
+7.19%
1 Year Est. Return
+15.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$836M
AUM Growth
+$219M
Cap. Flow
+$188M
Cap. Flow %
22.5%
Top 10 Hldgs %
4.49%
Holding
1,220
New
441
Increased
247
Reduced
213
Closed
319

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$4.41M
2
AAP icon
Advance Auto Parts
AAP
+$4.15M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.96M
4
DLTR icon
Dollar Tree
DLTR
+$3.82M
5
MSFT icon
Microsoft
MSFT
+$3.74M

Top Sells

Rank Stock Value
1
BAC icon
Bank of America
BAC
+$2.82M
2
KO icon
Coca-Cola
KO
+$2.82M
3
GD icon
General Dynamics
GD
+$2.82M
4
ORCL icon
Oracle
ORCL
+$2.81M
5
HLNE icon
Hamilton Lane
HLNE
+$2.8M

Sector Composition

Rank Sector Weight
1 Technology 16.51%
2 Industrials 15.72%
3 Consumer Discretionary 15.68%
4 Healthcare 13.43%
5 Financials 10.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CE icon
76
Celanese
CE
$4.87B
$2.23M 0.27%
16,397
+1,043
+7% +$137K
MSI icon
77
Motorola Solutions
MSI
$70.3B
$2.23M 0.27%
4,952
+3,327
+205% +$1.39M
HLT icon
78
Hilton Worldwide
HLT
$75.3B
$2.22M 0.27%
9,651
+4,167
+76% +$902K
META icon
79
Meta Platforms (Facebook)
META
$1.51T
$2.22M 0.27%
+3,886
New +$2M
EAT icon
80
Brinker International
EAT
$8.38B
$2.22M 0.27%
+29,037
New +$2M
NXT icon
81
Nextpower Inc
NXT
$15.7B
$2.22M 0.27%
+59,201
New +$2.47M
COR icon
82
Cencora
COR
$60.5B
$2.2M 0.26%
+9,774
New +$2.27M
NUVL
83
DELISTED
Nuvalent
NUVL
$2.2M 0.26%
+21,500
New +$1.78M
LLY icon
84
Eli Lilly
LLY
$1.07T
$2.18M 0.26%
+2,459
New +$2.21M
VTR icon
85
Ventas
VTR
$48.7B
$2.15M 0.26%
33,465
+7,728
+30% +$451K
ELAN icon
86
Elanco Animal Health
ELAN
$12.7B
$2.14M 0.26%
+145,645
New +$2.03M
UHS icon
87
Universal Health Services
UHS
$9.64B
$2.09M 0.25%
+9,142
New +$1.97M
J icon
88
Jacobs Solutions
J
$16B
$2.08M 0.25%
16,071
+5,936
+59% +$715K
STT icon
89
State Street
STT
$50.7B
$2.05M 0.25%
+23,162
New +$1.91M
CART icon
90
Maplebear
CART
$10.4B
$2.03M 0.24%
+49,778
New +$1.75M
EQIX icon
91
Equinix
EQIX
$103B
$2.03M 0.24%
2,283
+1,496
+190% +$1.23M
PG icon
92
Procter & Gamble
PG
$346B
$2.01M 0.24%
11,629
-991
-8% -$168K
ABBV icon
93
AbbVie
ABBV
$454B
$2M 0.24%
+10,110
New +$1.89M
VSTS icon
94
Vestis
VSTS
$2.03B
$1.99M 0.24%
133,869
-4,880
-4% -$65.5K
MELI icon
95
Mercado Libre
MELI
$92.3B
$1.99M 0.24%
969
+255
+36% +$480K
C icon
96
Citigroup
C
$223B
$1.99M 0.24%
+31,725
New +$1.96M
CRGY icon
97
Crescent Energy
CRGY
$3.46B
$1.97M 0.24%
+180,217
New +$2.06M
EIX icon
98
Edison International
EIX
$30.3B
$1.95M 0.23%
22,339
-1,682
-7% -$137K
WRBY icon
99
Warby Parker
WRBY
$3.05B
$1.94M 0.23%
118,812
+100,382
+545% +$1.51M
SITC icon
100
SITE Centers
SITC
$232M
$1.93M 0.23%
+163,628
New +$1.92M
2 3
4
5 6

Similar funds

SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
HIP
HPS Investment Partners New York $1.52B AUM 19.81% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return

Nebula Research & Development's Q3 2024 Portfolio in Review

As of Q3 2024, Nebula Research & Development held 1,220 positions worth $836M, up 35% from $618M the previous quarter. Its ten largest holdings account for 4.5% of the portfolio.

Nebula Research & Development deployed $188M of net new capital in Q3 2024, opening 441 new positions and adding to 247 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 52,699 shares worth $3.7M.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Industrials and Consumer Discretionary.

On the sell side, the largest reduction was Travelers Companies, an estimated $2.39M trimmed.

  • Nebula Research & Development's largest Q3 2024 buy was BioMarin Pharmaceuticals: 52,699 shares worth $3.7M.
  • Nebula Research & Development added most to Dollar Tree in Q3 2024, an estimated $3.82M increase.
  • Nebula Research & Development's biggest Q3 2024 reduction was Travelers Companies, cutting an estimated $2.39M.
  • Nebula Research & Development fully exited Bank of America in Q3 2024, selling an estimated $2.82M.
  • Nebula Research & Development's ten largest holdings make up 4.5% of its $836M portfolio in Q3 2024.
  • Nebula Research & Development opened 441 new positions and closed 319 in Q3 2024.
  • Nebula Research & Development's portfolio value rose 35% quarter-over-quarter to $836M.

Based on Nebula Research & Development's 13F filing for Q3 2024, filed 14 Nov 2024.